EGFR exon 20 insertion

Notes

original target text: EGFR exon 20 insertion inhibitor

Epidermal growth factor receptor (EGFR) is a cell-surface receptor tyrosine kinase that, when activated by growth factor binding, triggers intracellular signaling cascades controlling cell division and survival. In certain cancers, particularly non-small cell lung cancer, small insertions of extra genetic material within a specific region of the EGFR gene called exon 20 produce a receptor that is locked in an active, signaling-competent state without needing external growth factor stimulation. This drives uncontrolled proliferation. Unlike the more common EGFR mutations that respond well to earlier-generation EGFR-targeted therapies, exon 20 insertions alter the three-dimensional shape of the drug-binding pocket in a way that sterically excludes many standard EGFR inhibitors, conferring inherent resistance. This created a clinical need for inhibitors specifically engineered to accommodate or exploit the altered pocket geometry of exon 20 insertion mutants. Small-molecule inhibitors designed against this target aim to selectively block the constitutively active mutant kinase while sparing normal, wild-type EGFR found in healthy tissues such as skin and gut lining, since broad EGFR inhibition causes class-related toxicities like rash and diarrhea. This mechanism matters broadly in oncology because it represents a genetically defined subset of tumors requiring a distinct pharmacological approach rather than a one-size-fits-all EGFR blockade.